Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Li L, Wang XH, Williams C, Volsky B, Steczko O, Seaman MS, Luthra K, Nyambi P, Nadas A, Giudicelli V, Lefranc MP, Zolla-Pazner S, Gorny MK.

Mol Immunol. 2015 Aug;66(2):364-74. doi: 10.1016/j.molimm.2015.04.011. Epub 2015 May 18.

2.

Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

Li L, Wang XH, Banerjee S, Volsky B, Williams C, Virland D, Nadas A, Seaman MS, Chen X, Spearman P, Zolla-Pazner S, Gorny MK.

PLoS One. 2012;7(6):e39534. doi: 10.1371/journal.pone.0039534. Epub 2012 Jun 25.

3.

Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Gorny MK, Pan R, Williams C, Wang XH, Volsky B, O'Neal T, Spurrier B, Sampson JM, Li L, Seaman MS, Kong XP, Zolla-Pazner S.

Virology. 2012 Jun 5;427(2):198-207. doi: 10.1016/j.virol.2012.02.003. Epub 2012 Mar 7.

4.

Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer.

Li L, Wang XH, Banerjee S, Volsky B, Williams C, Moody MA, Zolla-Pazner S, Gorny MK.

Hum Antibodies. 2012;21(3-4):65-73. doi: 10.3233/HAB-130264.

5.

Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure.

Gorny MK, Sampson J, Li H, Jiang X, Totrov M, Wang XH, Williams C, O'Neal T, Volsky B, Li L, Cardozo T, Nyambi P, Zolla-Pazner S, Kong XP.

PLoS One. 2011;6(12):e27780. doi: 10.1371/journal.pone.0027780. Epub 2011 Dec 2.

6.

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A.

Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25.

7.

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, NĂ¡das A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S.

J Virol. 2006 Jul;80(14):6865-72.

8.

Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S.

J Virol. 2005 Apr;79(8):5232-7.

9.

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8.

PMID:
15588347
10.

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S.

J Virol. 2004 Mar;78(5):2394-404.

11.

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S.

J Virol. 2002 Sep;76(18):9035-45.

12.

Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, Burda S, Wang XH, Bandres J, Zolla-Pazner S, Holmes H.

Immunol Lett. 2001 Dec 3;79(3):209-13.

PMID:
11600200
13.

Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S.

J Virol. 1998 Sep;72(9):6988-96.

14.

Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Michael NL, Nelson JA, KewalRamani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, White GC 2nd, Littman DR, Swanstrom R, O'Brien TR.

J Virol. 1998 Jul;72(7):6040-7.

15.

A mechanism of restricted human immunodeficiency virus type 1 expression in human glial cells.

Shahabuddin M, Bentsman G, Volsky B, Rodriguez I, Volsky DJ.

J Virol. 1996 Nov;70(11):7992-8002.

16.
17.

Evaluation of multiple parameters of HIV-1 replication cycle in testing of AIDS drugs in vitro.

Volsky DJ, Li G, Hamblet N, Volsky B, Decker RS, Pellegrino MG, Potash MJ.

Antiviral Res. 1992 Apr;17(4):335-47.

PMID:
1322647
18.

Regulated expression of human immunodeficiency virus type 1 in human glial cells: induction of dormant virus.

Shahabuddin M, Volsky B, Kim H, Sakai K, Volsky DJ.

Pathobiology. 1992;60(4):195-205.

PMID:
1388716
19.
20.

Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA.

Stevenson M, Volsky B, Hedenskog M, Volsky DJ.

Science. 1986 Aug 29;233(4767):980-4.

PMID:
3016899
22.

Infection of normal human thymic epithelial cells by Epstein-Barr virus (EBV) following implantation of EBV receptors.

Seshi B, Volsky B, Anderson RW, Purtilo DT, Volsky DJ.

Thymus. 1984;6(1-2):5-13.

PMID:
6087504
23.

Production of infectious Epstein--Barr virus in mouse lymphocytes.

Volsky DJ, Klein G, Volsky B, Shapiro IM.

Nature. 1981 Oct 1;293(5831):399-401. No abstract available.

PMID:
6268991

Supplemental Content

Loading ...
Support Center